We are monitoring the impact of COVID-19 on MEA Biopharmaceuticals Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 586
Share on
Share on

Middle-East and Africa Biopharmaceuticals Market Research Report – Segmented By Product Type, Therapeutic Type & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 586
Pages: 145

MEA Biopharmaceuticals Market Size (2021 to 2026)

The size of the Middle East and Africa Biopharmaceuticals Market is estimated to grow USD 29.29 billion by 2026 from USD 18.90 billion in 2021, estimated to be growing at a CAGR of 9.16% during the forecast period.

The increased demand for biopharmaceuticals is being met by a greater focus on research and associated funding in MEA. In addition, biopharmaceutical products' potential to treat previously untreatable diseases has resulted in the introduction of novel medicines to the market. As a result of these factors, the market under consideration is anticipated to expand throughout the forecast period. The MEA biopharmaceuticals market is fueled by several reasons, including an aging population, growth in the frequency of chronic diseases, including cancer and diabetes, and a global increase in biopharmaceutical usage. Furthermore, the biopharmaceuticals business is expected to benefit from an increase in strategic alliances among pharmaceutical companies. Egypt and South Africa continue to generate double-digit growth in institutional sales. Saudi Arabia is the largest pharmaceutical market in the Middle East, accounting for 60% of the regional market, followed by the United Arab Emirates. Saudi Arabia boasts the largest industrial sector in the Gulf, although most of its output is headed for export. Domestic production contributes to around 17% of the market's total supply of medicines.

The majority of vaccine candidates under development are complex protein subunit vaccines, RNA, and DNA. This factor is expected to increase demand in the biopharmaceuticals market in the near future as the epidemic progresses. The ability of biopharmaceutical products to cure previously incurable diseases has led to the introduction of novel drugs to the market. In addition, in the near future, the desire to prevent the side effects associated with some small-molecule medications and invasive surgical procedures is anticipated to drive increasing demand in the biopharmaceuticals market. With governments in the region increasingly concentrating on the well-being of a rising population and improving healthcare services, timely and safe delivery of medical supplies and pharmaceutical goods has prepared the path for a promising future for the region's pharmaceutical sector. In the future, high life expectancy and rapid population increase are projected to stimulate demand for medicines. Higher healthcare demand has resulted from rising healthcare awareness and rising per capita income. The infant mortality rate has decreased considerably over time as a result of improved healthcare facilities and treatment.

The growth limiting factors for the researched market include rigorous regulatory difficulties and the necessity of a large investment in developing a biopharmaceutical medication. In addition, the high costs of deploying testing equipment are expected to hinder the MEA biopharmaceuticals market's expansion.

Stringent pharmaceutical procedures encountered by health practitioners, biopharmaceutical companies, and stakeholders are the main restraints on the market expansion. In addition, there are several challenges and obstacles involved with new medication discovery and the advertising of such unique treatments.

This research report on the MEA biopharmaceuticals market has been segmented and sub-segmented into the following categories:

By Product Type:

  • Monoclonal Antibodies (mAb)       
  • Erythropoietin       
  • Biotech Vaccines 
  • Recombinant Human (RH) Insulin
  • Granulocyte colony-stimulating factor (G-CSF)       
  • Interferon               
  • Human growth hormones (HGH)  

By Therapeutic Type: 

  • Neurology
  • Infectious Diseases
  • Diabetes
  • Oncology
  • Cardiovascular
  • Other Therapeutic Areas

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Regional Analysis:

Africa is leading most of the biopharmaceuticals market in this region due to the enlarging population and an increasing number of cases with lack of malnutrition. Furthermore, rising diseases like obesity and type-2 diabetes accelerate market growth. In addition, increasing demand for contributing quality services is enlarging the market share. Adopting unhealthy food habits and lack of proper knowledge over fitness are the significant factors surging the growth. However, high costs and side effects of biopharmaceuticals like breathing problems and allergies hamper the market growth.

In the Middle East, the growing incidences of non-contagious chronic diseases like diabetes, cardiovascular diseases, etc., have increased demand for the biopharmaceuticals market in this region. Furthermore, adopting unhealthy lifestyles and a lack of physical movement is one of the major factors driving demand for the biopharmaceuticals market. In addition, the increased number of people consuming alcohol and cigarettes has increased the need for the biopharmaceuticals market in this region.

In Africa, expanding population and rate of malnutrition are propelling the demand of the market. Furthermore, increasing diseases like obesity and type-2 diabetes will drive the demand for the market in this region. In addition, the rising need to promote quality services is expanding the shares of the market.

KEY MARKET PLAYERS:

Companies such as Merck & Co., Inc., F. Hoffmann-La Roche AG, Eli Lilly and Company, Inc., Sanofi, Amgen Inc., AbbVie Inc., Biogen Idec, Bayer AG, Johnson & Johnson Services, Pfizer, Inc. and Novartis AG are playing a dominant role in the MEA Biopharmaceuticals Market.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies (mAb)       

                                5.1.2 Erythropoietin       

                                5.1.3 Biotech Vaccines  

                                5.1.4 Recombinant Human (RH) Insulin 

                                5.1.5 Granulocyte colony-stimulating factor (G-CSF)       

                                5.1.6 Interferon               

                                5.1.7 Human growth hormones (HGH)  

                5.2 By Therapeutic Type                               

                                5.2.1 Neurology               

                                5.2.2 Infectious diseases              

                                5.2.3 Diabetes  

                                5.2.4 Oncology 

                                5.2.5 Cardiovascular       

                                5.2.6 Other Therapeutic Areas  

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 Middle-East                                

                6.3 Africa                            

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Merck & Co.                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Strategic Evaluation and Operations            

                                8.1.4 Financial analysis  

                                8.1.5 Legal issues             

                                8.1.6 Recent Developments       

                                8.1.7 SWOT analysis       

                                8.1.8 Analyst View          

                8.2 F. Hoffmann-La Roche AG                    

                8.3 Eli Lilly and Company                              

                8.4 Sanofi                           

                8.5 Amgen Inc.                 

                8.6 AbbVie Inc.                 

                8.7 Biogen Idec                

                8.8 Bayer AG                     

                8.9 Johnson & Johnson Services                               

                8.10 Pfizer                          

                8.11 Novartis AG                             

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Expert Opinions                                        

                10.1 Market Outlook                     

                10.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Biopharmaceuticals market By Region, From 2021 to 2026 (USD Billion)
  2. Middle East & Africa Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  3. Middle East & Africa Monoclonal Antibodies (mAb) Market By Region, From 2021 to 2026 (USD Billion)
  4. Middle East & Africa Erythropoietin Market By Region, From 2021 to 2026 (USD Billion)
  5. Middle East & Africa Biotech Vaccines Market By Region, From 2021 to 2026 (USD Billion)
  6. Middle East & Africa Recombinant Human (RH) Insulin Market By Region, From 2021 to 2026 (USD Billion)
  7. Middle East & Africa Granulocyte colony-stimulating factor (G-CSF) Market By Region, From 2021 to 2026 (USD Billion)
  8. Middle East & Africa Interferon Market By Region, From 2021 to 2026 (USD Billion)
  9. Middle East & Africa Human growth hormones (HGH) Market By Region, From 2021 to 2026 (USD Billion)
  10. Middle East & Africa Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)
  11. Middle East & Africa Neurology Market By Region, From 2021 to 2026 (USD Billion)
  12. Middle East & Africa Infectious diseases Market By Region, From 2021 to 2026 (USD Billion)
  13. Middle East & Africa Diabetes Market By Region, From 2021 to 2026 (USD Billion)
  14. Middle East & Africa Oncology Market By Region, From 2021 to 2026 (USD Billion)
  15. Middle East & Africa Cardiovascular Market By Region, From 2021 to 2026 (USD Billion)
  16. Middle East & Africa Other Therapeutic Areas Market By Region, From 2021 to 2026 (USD Billion)
  17. Middle East Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  18. Middle East Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)
  19. Africa Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  20. Africa Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample